Crossmark

Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

Crossref DOI link: https://doi.org/10.1186/s12891-021-03971-w

Published Online: 2021-01-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ueyama, Hideki

Ohta, Yoichi

Imai, Yuuki

Suzuki, Akinobu

Sugama, Ryo

Minoda, Yukihide

Takaoka, Kunio

Nakamura, Hiroaki
License Information

Text and Data Mining valid from 2021-01-20

Version of Record valid from 2021-01-20
More Information

Article History

Received: 15 August 2020

Accepted: 11 January 2021

First Online: 20 January 2021

Ethics approval and consent to participate

: All animal experiments were performed in strict accordance with the regulations of the Institutional Animal Care and Use Committee, Osaka City University Medical School (Approval number: 13017).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below